The Business of Biofabrication

Six Horizon Europe projects are collaborating across corneal, colorectal, liver, orthopedic and urological regeneration. Their work reveals how biofabrication is moving beyond standalone printers toward complete clinical manufacturing systems.

Europe has quietly assembled one of the most ambitious coordinated investments in regenerative bioprinting to date.

The newly established European Bioprinting Cluster brings together six Horizon Europe projects—m2M, TENTACLE, LUMINATE, STRONG-UR, NEOLIVER and KeratOPrinter—working on applications ranging from cartilage and corneal regeneration to urethral reconstruction and bioprinted liver tissue. Together, the projects represent approximately €46.8 million in European Union funding, with most running from 2024 or 2025 through 2028 or 2029.

It is important to understand what the cluster is—and what it is not. These are not six conventional bioprinting companies selling finished products. They are multinational research consortia that combine universities, hospitals, clinicians, materials developers, equipment companies and commercialization specialists. Their technologies remain largely in research and preclinical development.

Nevertheless, the cluster may be an important indicator of where biofabrication is heading.

Six Projects, Six Clinical Problems

The projects are distributed across Europe, with m2M coordinated by Trinity College Dublin in Ireland, TENTACLE by University Hospital Würzburg in Germany, LUMINATE by the University of Pisa in Italy, STRONG-UR by Aalborg University in Denmark, NEOLIVER by Utrecht University in the Netherlands and KeratOPrinter by Tampere University in Finland.

Although all six programs involve bioprinting, they approach the technology from markedly different clinical directions.

The m2M project is developing a platform for arranging cellular aggregates and microtissues into larger, personalized grafts. Rather than attempting to print every feature of a mature tissue directly, m2M intends to provide biological building blocks with scaffolds and spatial cues that guide their subsequent fusion, remodeling and maturation. Its initial applications include cartilage, osteochondral and maxillofacial repair.

TENTACLE is developing a colonoscopic bioprinting system for the regeneration of colorectal mucosa and submucosa. Its proposed system combines extrusion, valve-based printing, mesh delivery, photocrosslinking and patient-cell-containing bioinks. One formulation is intended to change shape after printing to reproduce the crypt-like architecture of colorectal tissue.

LUMINATE is working toward a minimally invasive, single-stage treatment for large osteochondral injuries in joints such as the knee. Its EndoFLight platform is designed to combine microextrusion, jetting and light-based fabrication so that cells, biomaterials and biological signals can be deposited directly into an injury through an arthroscopic procedure.

STRONG-UR focuses on tubular tissue reconstruction for urethral strictures. The project is pursuing both an in-situ printing method and a multistage approach involving GMP-manufactured components. It also plans to develop modular printer components, personalized smart bioinks and a bioprinted urethral model for preclinical testing.

At the other end of the complexity spectrum, NEOLIVER aims to create dense, vascularized liver constructs from patient-derived organoids, spheroids, endothelial cells and supporting cell populations. The project plans to combine laser-induced forward transfer with extrusion-printed vascular structures and eventually evaluate the constructs through transplantation into immunodeficient pigs.

Finally, KeratOPrinter is developing a full-thickness, native-like bioprinted human cornea. Its program includes scalable cell sources, multiple bioinks, high-resolution printing, in-process monitoring, surgical handling, GMP manufacturing, GLP studies and regulatory planning. The consortium has set a long-term ambition of enabling vision-restoring therapy by 2035.

The Printer Is No Longer the Product

The most important lesson from the cluster is that the field is no longer treating the printer as the complete innovation.

Each project is developing a broader therapeutic system. That system may include patient-derived cells, organoids, bioinks, synthetic scaffolds, imaging, surgical delivery devices, process controls, maturation protocols, vascularization strategies and regulatory documentation. The printer remains important, but it is becoming one component within a much larger manufacturing and clinical workflow.

This represents a meaningful change from the earlier commercial era of bioprinting. For much of the past decade, companies primarily competed on hardware specifications: the number of printheads, positional accuracy, temperature control, extrusion pressure or the range of printable materials.

Those capabilities remain necessary, but they are insufficient for clinical translation.

A tissue product must be reproducible across batches. Its cells must maintain identity and function. Its materials must degrade or remodel predictably. The construct must survive transport, handling and implantation. Its manufacturing process must operate under appropriate quality systems. Regulators must be able to understand what the product is, how it is controlled and how its risks will be evaluated.

The European Bioprinting Cluster has consequently organized its collaboration around three working groups: commercialization, compliance with standards and regulations, and communication and dissemination. That structure demonstrates that translation is being treated as a shared technical challenge rather than something to be addressed only after the science is complete.

In-Situ Bioprinting Is Emerging as a Distinct Category

Another significant development is the prominence of in-situ bioprinting.

TENTACLE proposes printing through a colonoscope. LUMINATE is developing an arthroscopic printing platform for osteochondral lesions. STRONG-UR includes an in-situ strategy for urethral reconstruction. Rather than manufacturing a tissue entirely in a laboratory and subsequently implanting it, these systems would deposit cells and materials directly at the site of injury.

This could create an entirely new category of biofabrication equipment.

Future bioprinters may increasingly resemble surgical instruments rather than desktop manufacturing systems. They may include endoscopic printheads, handheld devices, robotic positioning, real-time imaging, light-delivery systems, sterile disposable cartridges and software capable of adapting a print to the patient’s anatomy during a procedure.

That transition would also change the competitive landscape. Medical-device companies, imaging businesses, surgical robotics developers and cell-therapy manufacturers may become as relevant to bioprinting as conventional additive-manufacturing companies.

From Perfect Tissues to Developmental Templates

The cluster also reflects a changing biological philosophy.

Early visions of bioprinting often implied that a machine would reproduce a finished organ layer by layer, precisely placing every cell and structural feature. Several of these projects instead treat printing as a way to establish an initial developmental template.

m2M seeks to position microtissues within guiding structures that support remodeling over several years. TENTACLE is designing materials that change shape after deposition. NEOLIVER relies on organoids and spheroids that already contain elements of biological self-organization.

The objective is therefore not necessarily to print a mature tissue in its final form. It may be to manufacture the appropriate cells, architecture, mechanical environment and biological instructions so the tissue can continue developing after fabrication or implantation.

This is a more realistic—but also more complex—vision of biofabrication. The machine provides spatial control, while biology performs part of the remaining construction.

What It Means for the Biofabrication Industry

For equipment companies, this cluster is both validation and a warning.

It validates that substantial institutions continue to invest in bioprinting. These programs will need reliable deposition systems, printheads, biomaterial handling, software, process monitoring, sterile workflows, custom engineering and technical support. They may also produce new spinouts, intellectual property and clinically oriented manufacturing platforms.

At the same time, the programs demonstrate that selling general-purpose research printers will not be enough to capture the greatest value.

The strongest platforms will likely be those that help researchers move from a promising experiment to a controlled manufacturing process. This means supporting multiple fabrication modalities, documenting process parameters, measuring critical quality attributes, integrating biological materials and adapting equipment to specific clinical workflows.

Customers would not simply purchase a printer. They would gain access to a process-development infrastructure capable of transforming a biological concept into something reproducible, scalable and eventually approvable.

Ambition Must Still Be Separated From Evidence

The scale of the cluster should not be mistaken for evidence that transplantable printed organs or routine in-situ bioprinting procedures have arrived.

The descriptions published by the projects state their objectives. They do not represent completed clinical outcomes. NEOLIVER’s intention to create an autologous liver construct suitable for transplantation is extraordinarily ambitious. KeratOPrinter’s full-thickness cornea must still satisfy demanding optical, biological, mechanical and manufacturing requirements. In-situ systems must prove that they can operate safely and reproducibly within complex surgical environments.

Many technical questions remain unresolved, including vascular integration, immune response, cell sourcing, tissue maturation, manufacturing cost, quality-control sampling and the regulatory classification of products that combine cells, biomaterials, software and medical devices.

Some projects will almost certainly change direction. Others may produce enabling technologies rather than the complete therapy described at their outset. Even an unsuccessful attempt to manufacture an entire tissue could generate valuable bioinks, printheads, cell-production methods, disease models or process-control technologies.

A More Mature Chapter for Bioprinting

The importance of the European Bioprinting Cluster is therefore not that six finished therapies are approaching the market.

Its importance is that six large consortia are attempting to address biofabrication as a complete translational discipline.

They are beginning with defined clinical problems rather than asking only what a printer can fabricate. They are involving clinicians, manufacturers and regulatory specialists earlier. They are exploring direct surgical printing, self-organizing microtissues, patient-derived materials, GMP production and in-process quality control.

The field is gradually moving beyond the question:

Can living cells be printed into a recognizable structure?

The more consequential questions are now:

Can the resulting tissue perform a clinically meaningful function? Can it be manufactured repeatedly? Can it be delivered safely? And can a healthcare system realistically adopt it?

Europe’s investment does not guarantee that the projects will answer all of those questions. It does, however, show that biofabrication is entering a more serious stage—one in which biological performance, manufacturing infrastructure and clinical translation matter more than the spectacle of printing alone.